Northwest Biotherapeutics (NWBO) has newer patents and in-licensed technologies (like in June 2024) that enhance their dendritic cell (DC) therapies, potentially strengthening IP around DCVax-L and related products by covering improved DC versions, manufacturing, and tumor microenvironment approaches, but these aim to protect their product development, not prevent others from using their licensed tech for NWBO's own use.
Key IP Developments for NWBO:
2024 In-License: In June 2024, NWBO announced licensing new patents filed in 2023 covering advanced DC-based therapies, conditioning regimens, and reprogramming tumor environments, adding significant new IP life to their portfolio.
Existing IP: NWBO already holds patents and pending applications for its DCVax products, including manufacturing processes, in various jurisdictions like Japan.
DCVax-L vs. DCVax-Direct: Their products, including DCVax-L (from tumor lysate) and DCVax-Direct (injecting cells directly into tumors), use patent-protected methods to mature dendritic cells.
How This Relates to DCVax-L:
These newer patents bolster NWBO's intellectual property around dendritic cell technology, which underpins DCVax-L.
They aim to protect NWBO's innovations and market position for their own DC-based vaccines, rather than restrict NWBO's ability to develop or use DCVax-L itself.
In essence, NWBO's patent strategy focuses on expanding and securing their own technological advantage in the dendritic cell space, including for their DCVax-L product line, through new filings and licensing.

Yes, other forms of legal protection beyond standard patents may prevent competitors from using Northwest Biotherapeutics' (NWBO) DCVax technology, primarily through regulatory exclusivity and potentially trade secrets.
Regulatory Exclusivity
Regulatory exclusivity is a separate form of protection granted by government regulatory bodies like the FDA in the U.S. or the EMA in Europe, provided specific criteria are met. It bars competitors from obtaining marketing approval for the same drug for a set period, regardless of patent status.
Orphan Drug Exclusivity (ODE): This is a key potential protection for DCVax-L, which is used for brain cancer (glioblastoma multiforme), a rare disease. If the drug receives FDA approval with an Orphan Drug Designation, it is generally entitled to a seven-year market exclusivity period in the U.S.. In Europe, this period is typically ten years.
Data Exclusivity: Regulatory authorities require the original applicant to submit extensive data from preclinical and clinical trials. Data exclusivity prevents subsequent applicants from relying on this data to support their own marketing applications for a specified period (e.g., five years for a new chemical entity in the U.S.), forcing them to conduct their own expensive and time-consuming trials.
Trade Secrets
NWBO may also protect certain aspects of its technology, such as specific manufacturing processes (like the Flaskworks system for a closed manufacturing process), as trade secrets. Unlike patents, which require public disclosure of the invention, trade secrets rely on keeping information confidential. This protection can theoretically last indefinitely as long as the information remains secret and reasonable efforts are made to maintain its confidentiality.
In summary, NWBO employs an integrated strategy for intellectual property protection that combines a substantial patent portfolio with other mechanisms, such as seeking Orphan Drug status, to protect its technology from competitors.

Yes, Northwest Biotherapeutics' (NWBO) DCVax technology is protected by a portfolio of patents. These patents cover various aspects, including manufacturing processes, the composition of the therapy, and methods of use.
The duration of protection varies by individual patent, but generally, a U.S. utility patent provides exclusive rights for 20 years from its filing date.
Key details regarding NWBO's patent portfolio:
Multiple Patents: NWBO has an integrated strategy involving numerous issued patents and many more pending in the U.S. and internationally.
Broad Coverage: The patents cover the use of dendritic cells in specific DCVax products, unique manufacturing processes (including automation), and methods for producing more potent dendritic cells.
Recent Additions: In June 2024, NWBO announced an exclusive license for an additional portfolio of dendritic cell technologies, which includes five new patent families filed in 2023. These newly filed patents have their full potential patent life ahead of them (up to 2043).
Patent Expirations: Specific patent expiration dates vary. For example, one patent mentioned in a third-party analysis (US8673893) has an expiration date in July 2028, but this is only one of many patents in their portfolio. The company has consistently asserted its "freedom to operate" regarding other parties' patents.
The company actively manages its intellectual property to ensure robust protection and the ability to scale up manufacturing of its DCVax products.

Yes, you can patent an improvement, but the original patent owner still owns their original patent and you'd likely need their permission (a license) to sell your improved product because it incorporates their patented invention; you'll have your own patent for the improvement, but they have rights to the base technology, creating a situation where both parties might need licenses from each other.
How it Works
Your Improvement is Patentable: If your improvement is novel, useful, and non-obvious, you can get your own patent (a "improvement patent") for the new features you added.
Infringement Risk: You cannot legally make, use, or sell your improved product without a license from the original patent holder if your invention still uses the core elements of their existing patent.
Cross-Licensing: The original owner can't make or sell your improved version without a license from you (for your improvements), and you can't sell it without a license from them (for the base invention). This often leads to cross-licensing agreements.
Your Patent Covers the Difference: Your patent protects the new, improved parts, not the entire original invention.

Press Release
20 NOV 2025
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
BETHESDA, Md., November 20, 2025 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out the construction of the first Grade C manufacturing suite in the Company’s Sawston, UK facility, the construction firm is onsite and the construction activities have begun. The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined. As such, the Company considers the construction of the first Grade C suite a major step towards potential large scale-up of the Company’s production of DCVax® products.

Manufacturing of medical products such as DCVax must be done in clean room facilities in sterile conditions. When manufacturing equipment and procedures involve steps open to the air, the manufacturing must take place in Grade B suites with special air handling and other requirements which are extremely expensive both to develop and to operate. In addition, only one patient’s product may be made in a Grade B suite at a time, and the whole suite must stop activity and be specially cleaned in between manufacturing one patient’s product and the next. The manufacturing of living cell products in general has traditionally had to be conducted in Grade B suites.
When a medical product is able to be manufactured using closed equipment and procedures that are not open to the air, the manufacturing can be conducted in Grade C manufacturing suites which are much less onerous and expensive to operate. In addition, multiple or numerous patient products may be manufactured simultaneously in a single Grade C manufacturing, and only certain equipment (not the whole suite) must be cleaned between production batches. These differences can enable a major increase in throughput and capacity, together with efficiency gains in both staff and materials. As the Company has previously reported, the Flaskworks system is specially designed to carry out the key manufacturing processes for DCVax-L products on a closed basis. Developing this system was particularly challenging because the DCVax-L manufacturing process includes the dendritic cells adhering like barnacles to the flasks containing them, and then the mature activated cells being harvested by detaching them without damaging or destroying them. The Company views use of the
Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites rather than Grade B suites – and the Company views such transition to Grade C suites as central to large scale-up of production.

The Company’s business plan currently envisions manufacturing being established in the Grade C suite in the Sawston facility during Q2 of next year, with the construction of the Grade C suite taking approximately 6 months, followed by equipment installation and validation. As previously reported, Advent worked closely with construction and engineering experts to develop a design and location within the Sawston facility that is expected to enable this first Grade C manufacturing suite to be constructed on a simplified basis at significantly lower construction costs and faster timeline. The project will also involve several million pounds of equipment costs.
For example, as noted in the Company’s recent 10-Q report, the cost to purchase certain fundamental equipment new is about £800,000 (approximately $1 million) per machine. Fortunately, Advent has been able to secure some of the machines at reduced cost. Due to long lead times, the Company is necessarily already proceeding with certain equipment purchases now. “We are excited to be under way with the construction activity and equipment sourcing for the first Grade C lab in our Sawston facility,” commented Linda Powers, the Company’s CEO. “We view this as a transformative step in our progress toward large scale operations.”

earlier this year, that we had developed a plan for a simplified C lab to build one on a simplified basis in a different location. It actually happens to be adjacent to the quarantine storage and loading docks, where far less infrastructure work has to be done, and it cut to less than half the cost of the design of the original C lab.

That's the one where we mentioned in our most recent quarterly report, Q3, that the contractor has already been selected and engaged, already been on site doing the prep work of the site, and we currently anticipate that the physical construction work would get underway at some point by the end of January for that, and then would be around a six-month timeframe to get finished for that.

Lastly on the clinical is compassionate use. Our compassionate use program is ongoing. We have a steady stream of inquiries and requests that come in. We're in the process now of expanding to additional doctors. A number of doctors have become interested, and we're also in exploratory discussions with a private hospital chain that has numerous locations.

In the new year, we currently plan to offer compassionate use treatments for most types of solid tumor cancers, not just brain cancer, thanks to the expertise and the interest of these additional doctors. And we also are planning at a certain point to offer DCVax-Direct in addition to DCVax-L for compassionate use. So that will be a very important progression of our compassionate use program.

Hi I am XXXXXXXXXXX a long time investor in NWBO.
I have the following questions I would like to submit for discussion at the ASM.
(1) Is MHRA approval expected soon and why has it taken so long?
(2) Is approval anticipated only for DCVAX-L for GBM or will it be for DCVAX-L for other solid tumor cancers as well?
(3) I thought NWBO had announced that DCVAX-Direct phase-3 was going to start earlier in 2025. It has not yet started so is it going to happen and when?
(4) How much longer is it going to take to have Flaskworks fully automated closed system manufacturing approved, on-line and operational? Are we still working out some issues with functionality and when would we hope to submit it for approval?
That is probably enough tough questions that may be difficult to answer.

Merry Christmas and Thanks
XXXXXXXXXX

Northwest Biotherapeutics (NWBO) SEC filings include "equivalency studies" as a risk factor, noting that changes in manufacturing methods could necessitate such studies or additional clinical trials. However, recent filings indicated no regulatory friction regarding "comparability" during the review process for its Marketing Authorization Application. You can find NWBO's official SEC filings through the SEC's EDGAR database.

Citadel LLC and Citadel Securities LLC do not publish a specific "annual report failure to deliver" document. Failure to Deliver (FTD) data for individual firms like Citadel is generally not available in their public financial statements or annual reports.
Instead, information regarding Citadel's FTDs and related violations is found in regulatory filings, press releases from agencies such as the SEC and FINRA, and disciplinary action reports.
Key findings related to Citadel and failures/misreporting include:
Regulatory Fines: Citadel Securities has been fined multiple times by regulators for various reporting failures and other violations.
Recent Reporting Violations: In October 2024, FINRA fined Citadel Securities $1 million for failing to timely and accurately report data for tens of billions of equity and option order events to the Consolidated Audit Trail (CAT) repository between June 2020 and August 2024.
Prior Reg SHO Violations: In September 2023, the SEC charged Citadel Securities with violating Regulation SHO (which governs short sales) due to a coding error that caused millions of orders to be incorrectly marked as "long" or "short" over a five-year period (2015-2020), resulting in a $7 million penalty.
General FTD Data: The official SEC FTD data is published in a raw format and does not identify the specific firms responsible for the fails. The data is cumulative and reported for the market as a whole, not broken down by individual firm in public reports.

Have Fun Swimming with Sharks

The annual global revenue for the oncology drugs market was about $201.75 billion in 2023, but this figure includes more than just chemotherapy, encompassing targeted therapies, immunotherapies, and more. The global market for all oncology drugs is projected to reach over $518 billion by 2032, growing at an 11.3% compound annual growth rate (CAGR).